Opendata, web and dolomites

FluAttack SIGNED

Validation of a novel antiviral drug candidate against influenza

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FluAttack project word cloud

Explore the words cloud of the FluAttack project. It provides you a very rough idea of what is the project "FluAttack" about.

options    virus    lt    plan    context    start    urgently    million    commercial    devastating    vaccination    innovative    ic50    with    epithelial    respect    3d    screening    lives    few    molecules    anti    licensing    trials    tests    characterise    data    infections    potent    poc    repurposing    preclinical    extremely    preventing    hits    drug    molecule    function    family    pandemic    world    agent    vivo    creation    health    hit    rely    perfect    candidate    reduce    limitations    pandemics    cells    ipr    burden    100nm    cancer    validate    organization    demand    went    societies    cellular    viral    solutions    compounds    model    650    approved    prevent    time    strategy    predicted    antivir    powerful    escape    efficacy    erc    agree    advantage    stg    replication    airway    deaths    resistance    human    worldwide    inhibitors    actually    risk    influenza    viruses    mouse    therapeutic    lab    severe    action    mode    limited    secure    treat    pathogens    heavy    economic    patent    specialists    clinical    infection    solution   

Project "FluAttack" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2021-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 139˙081.00
2    CNRS INNOVATION FR (PARIS) participant 10˙919.00

Map

 Project objective

With 3 to 5 million severe cases and up to 650,000 deaths per year worldwide, influenza viruses are not only major human pathogens, they are also a heavy economic burden to our societies. In addition, influenza pandemics can occur at any time with potential devastating effects in terms of lives and costs. Solutions to prevent infection, to treat severe influenza cases and to respond to a severe pandemic are currently extremely limited and rely on vaccination and on only few approved molecules. All these solutions have their limitations with respect to efficacy and all face the problem of viral resistance. Thus, the demand for new options against influenza infections is high. The World Health Organization (WHO) and influenza virus specialists agree that innovative and effective anti-influenza compounds with a reduced risk of viral escape are urgently needed. The main goal of this ERC PoC is to provide key data on a promising innovative therapeutic solution identified in the lab. Taking advantage of a powerful screening system we have developed during the ERC StG ANTIViR, we have identified a family of molecules as potent inhibitors of influenza virus (with IC50<100nM). The mode of action of these molecules is known and they actually target a cellular function essential to all influenza viruses. Preventing viral replication by targeting a cellular function is a novel approach, predicted to strongly reduce the risk of drug resistance. Importantly, one of our hits went through several phase II and III clinical trials as an anti-cancer agent, making this molecule a perfect candidate for drug repurposing. In this context, the specific objectives of this ERC PoC are: i) to further characterise and validate our best hit, in particular in commercial 3D human airway epithelial cells and in vivo in a mouse model, and ii) to secure IPR and to establish an exploitation strategy plan (patent licensing or creation of a start-up) to support future development and preclinical tests.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FLUATTACK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FLUATTACK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

KineTic (2020)

New Reagents for Quantifying the Routing and Kinetics of T-cell Activation

Read More  

E-DURA (2018)

Commercialization of novel soft neural interfaces

Read More  

EASY-IPS (2019)

a rapid and efficient method for generation of iPSC

Read More